litlas
ログインアカウント作成

Gerald S. Falchook

2011–2025 年に発表

別表記
Gerald S Falchook
119
論文数
23,569
被引用数
66
h 指数
113
i10 指数

被引用数

Gerald S. Falchook の年別被引用数1995 年: 被引用 1 件1997 年: 被引用 1 件2001 年: 被引用 1 件2004 年: 被引用 2 件2010 年: 被引用 2 件2011 年: 被引用 16 件2012 年: 被引用 95 件2013 年: 被引用 301 件2014 年: 被引用 349 件2015 年: 被引用 333 件2016 年: 被引用 278 件2017 年: 被引用 286 件2018 年: 被引用 230 件2019 年: 被引用 662 件2020 年: 被引用 929 件2021 年: 被引用 1,354 件2022 年: 被引用 1,280 件2023 年: 被引用 1,127 件2024 年: 被引用 1,560 件2025 年: 被引用 940 件2026 年: 被引用 34 件1996 年は被引用が無いため表示していません1998〜2000 年は被引用が無いため表示していません2002〜2003 年は被引用が無いため表示していません2005〜2009 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 3,531 件、この内訳の 28.6%中国: 引用元論文 1,434 件、この内訳の 11.6%イタリア: 引用元論文 722 件、この内訳の 5.9%イギリス: 引用元論文 626 件、この内訳の 5.1%ドイツ: 引用元論文 574 件、この内訳の 4.7%フランス: 引用元論文 505 件、この内訳の 4.1%スペイン: 引用元論文 431 件、この内訳の 3.5%オーストラリア: 引用元論文 397 件、この内訳の 3.2%日本: 引用元論文 384 件、この内訳の 3.1%カナダ: 引用元論文 325 件、この内訳の 2.6%オランダ: 引用元論文 316 件、この内訳の 2.6%スイス: 引用元論文 285 件、この内訳の 2.3%
0%28.6%その他 22.7%

機関

分野

  • Medicine45.5%
  • Biochemistry, Genetics and Molecular Biology45.5%
  • Immunology and Microbiology4.2%
  • Computer Science1.2%
  • Chemistry1.1%
  • Materials Science0.5%
  • その他2%

トピック

  • Melanoma and MAPK Pathways5.4%
  • Lung Cancer Treatments and Mutations4.9%
  • Cancer Genomics and Diagnostics4.5%
  • Cancer Immunotherapy and Biomarkers4.5%
  • Colorectal Cancer Treatments and Studies2.7%
  • PI3K/AKT/mTOR signaling in cancer2.5%
  • その他75.5%

共著者

全論文

検索で開く
  1. Sotorasib for Lung Cancers with KRAS p.G12C Mutation

    著者: Ferdinandos Skoulidis, Bob T. Li, Grace K. Dy, Timothy Price, Gerald S. Falchook, Jürgen Wolf, Antoîne Italiano, Martin Schüler, Hossein Borghaei, Fabrice Barlési, Terufumi Kato, Alessandra Curioni‐Fontecedro, Adrian G. Sacher, Alexander I. Spira, Suresh S. Ramalingam, Toshiaki Takahashi, Benjamin Besse, Abraham Anderson, Agnes Ang, Qui Tran, Omar Mather, Haby Henary, Gataree Ngarmchamnanrith, Gregory Friberg, Vamsidhar Velcheti, Ramaswamy Govindan - New England Journal of Medicine 2021 被引用: 1,769

  2. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity

    著者: Jude Canon, Karen Rex, Anne Y. Saiki, Christopher Mohr, Keegan S. Cooke, Dhanashri Bagal, Kevin Gaida, Tyler Holt, Charles G. Knutson, Neelima Koppada, Brian A. Lanman, Jonathan Werner, Aaron S. Rapaport, Tisha San Miguel, Roberto Ortiz, Tao Osgood, Ji-Rong Sun, Xiaochun Zhu, John D. McCarter, Laurie P. Volak, Brett E. Houk, Marwan Fakih, Bert H. O’Neil, Timothy Price, Gerald S. Falchook, Jayesh Desai, James Kuo, Ramaswamy Govindan, David S. Hong, Wenjun Ouyang, Haby Henary, Tara Arvedson, Victor J. Cee, J. Russell Lipford - Nature 2019 被引用: 2,303

  3. KRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors

    著者: David S. Hong, Marwan Fakih, John H. Strickler, Jayesh Desai, Gregory A. Durm, Geoffrey I. Shapiro, Gerald S. Falchook, Timothy Price, Adrian G. Sacher, Crystal S. Denlinger, Yung‐Jue Bang, Grace K. Dy, John C. Krauss, Yasutoshi Kuboki, James Kuo, Andrew L. Coveler, Keunchil Park, Tae Won Kim, Fabrice Barlési, Pamela N. Münster, Suresh S. Ramalingam, Timothy F. Burns, Funda Meric‐Bernstam, Haby Henary, Jude Ngang, Gataree Ngarmchamnanrith, June Myung Kim, Brett E. Houk, Jude Canon, J. Russell Lipford, Gregory Friberg, Piro Lito, Ramaswamy Govindan, Bob T. Li - New England Journal of Medicine 2020 被引用: 1,687

  4. Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours

    著者: David S. Hong, Yoon‐Koo Kang, Mitesh J. Borad, Jasgit C. Sachdev, Samuel Ejadi, Ho Yeong Lim, Andrew Brenner, Keunchil Park, Jae‐Lyun Lee, Tae‐You Kim, SangJoon Shin, Carlos Becerra, Gerald S. Falchook, Jay Stoudemire, Desiree Martin, Kevin Kelnar, Heidi J. Peltier, Vinícius Bonato, Andreas G. Bader, Susan Smith, Sinil Kim, Vincent O’Neill, Muhammad Shaalan Beg - British Journal of Cancer 2020 被引用: 912

  5. Sotorasib in KRAS p.G12C–Mutated Advanced Pancreatic Cancer

    著者: John H. Strickler, Hironaga Satake, Thomas J. George, Rona Yaeger, Antoine Hollebecque, Ignacio Garrido‐Laguna, Martin Schüler, Timothy F. Burns, Andrew L. Coveler, Gerald S. Falchook, Mark Vincent, Yu Sunakawa, Laëtitia Dahan, David L. Bajor, Sun Young Rha, Charlotte Lemech, Dejan Juric, Marko Rehn, Gataree Ngarmchamnanrith, Pegah Jafarinasabian, Qui Tran, David S. Hong - New England Journal of Medicine 2022 被引用: 468

  6. Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer

    著者: Alexander Drilon, Geoffrey R. Oxnard, Daniel Shao-Weng Tan, Herbert H. Loong, Melissa L. Johnson, Justin F. Gainor, Caroline E. McCoach, Oliver Gautschi, Benjamin Besse, Byoung Chul Cho, Nir Peled, Jared Weiss, Yu-Jung Kim, Yuichiro Ohe, Makoto Nishio, Keunchil Park, Jyoti D. Patel, Takashi Seto, Tomohiro Sakamoto, Ezra Y. Rosen, Manisha H. Shah, Fabrice Barlési, Philippe A. Cassier, Lyudmila Bazhenova, Filippo de Braud, Elena Garralda, Vamsidhar Velcheti, Miyako Satouchi, Kadoaki Ohashi, Nathan A. Pennell, Karen L. Reckamp, Grace K. Dy, Jürgen Wolf, Benjamin Solomon, Gerald S. Falchook, Kevin Ebata, Michele Nguyen, Binoj C. Nair, Edward Y. Zhu, Luxi Yang, Xin Huang, Elizabeth Olek, S. Michael Rothenberg, Kōichi Goto, Vivek Subbiah - New England Journal of Medicine 2020 被引用: 836

  7. First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors

    著者: Gerald S. Falchook, Jeffrey R. Infante, Hendrik‐Tobias Arkenau, Manish R. Patel, Emma Dean, Erkut Borazanci, Andrew Brenner, Natalie Cook, Juanita Lopez, Shubham Pant, Arthur E. Frankel, Peter Schmid, Kathleen N. Moore, William McCulloch, Katharine Grimmer, Marie O’Farrell, George Kemble, Howard A. Burris - EClinicalMedicine 2021 被引用: 275

  8. Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial

    著者: Marwan G Fakih, Scott Kopetz, Yasutoshi Kuboki, Tae Won Kim, Pamela N Munster, John C Krauss, Gerald S Falchook, Sae-Won Han, Volker Heinemann, Kei Muro, John H Strickler, David S Hong, Crystal S Denlinger, Gustavo Girotto, Myung-Ah Lee, Haby Henary, Qui Tran, Joseph K Park, Gataree Ngarmchamnanrith, Hans Prenen, Timothy J Price - The Lancet Oncology 2021 被引用: 288

  9. Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

    著者: Keith T. Flaherty, J. Infante, Adil Daud, René González, Richard Kefford, Jeffrey A. Sosman, Omid Hamid, Lynn M. Schuchter, Jonathan Cebon, Nageatte Ibrahim, Ragini R. Kudchadkar, Howard A. Burris, Gerald S. Falchook, Alain P. Algazi, Karl D. Lewis, Georgina V. Long, Igor Puzanov, Peter F. Lebowitz, Ajay P. Singh, Shonda M Little, Peng Sun, Alicia J. Allred, Danièle Ouellet, Kevin B. Kim, Kiran Patel, Jeffrey S. Weber - New England Journal of Medicine 2012 被引用: 2,798

  10. Long-Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients With Pretreated KRAS G12C-Mutated Non–Small-Cell Lung Cancer: 2-Year Analysis of CodeBreaK 100

    著者: Grace K. Dy, Ramaswamy Govindan, Vamsidhar Velcheti, Gerald S. Falchook, Antoîne Italiano, Jürgen Wolf, Adrian G. Sacher, Toshiaki Takahashi, Suresh S. Ramalingam, Christophe Dooms, Dong‐Wan Kim, Alfredo Addeo, Jayesh Desai, Martin Schüler, Pascale Tomasini, David S. Hong, Piro Lito, Qui Tran, Simon Jones, Abraham Anderson, Antreas Hindoyan, Wendy Snyder, Ferdinandos Skoulidis, Bob T. Li - Journal of Clinical Oncology 2023 被引用: 149

  11. PEGylated IL-10 (Pegilodecakin) Induces Systemic Immune Activation, CD8+ T Cell Invigoration and Polyclonal T Cell Expansion in Cancer Patients

    著者: Aung Naing, Jeffrey R. Infante, Kyriakos P. Papadopoulos, Ivan H. Chan, Cong Shen, Navneet Ratti, Bianca Rojo, Karen A. Autio, Deborah J. Wong, Manish R. Patel, Patrick A. Ott, Gerald S. Falchook, Shubham Pant, Annie Hung, Kara Pekarek, Victoria H. Wu, Matthew Adamow, Scott McCauley, John B. Mumm, Phillip Wong, Peter Van Vlasselaer, Joseph A. Leveque, Nizar M. Tannir, Martin Oft - Cancer Cell 2018 被引用: 251

  12. Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53

    著者: Mansoor N. Saleh, Manish R. Patel, Todd M. Bauer, Sanjay Goel, Gerald S. Falchook, Geoffrey I. Shapiro, Ki Y. Chung, Jeffrey R. Infante, Robert M. Conry, Guilherme Rabinowits, David S. Hong, Judy S. Wang, Ulrich Steidl, Gurudatta Naik, Vincent Guerlavais, Vojislav Vukovic, D. Allen Annis, Manuel Aivado, Funda Meric‐Bernstam - Clinical Cancer Research 2021 被引用: 147

  13. Protein Arginine Methyltransferase 5 (PRMT5) Inhibitors in Oncology Clinical Trials: A review

    著者: Kavanya Feustel, Gerald S. Falchook - Journal of Immunotherapy and Precision Oncology 2022 被引用: 125

  14. Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600–Mutant Colorectal Cancer

    著者: Ryan B. Corcoran, Chloé E. Atreya, Gerald S. Falchook, Eunice L. Kwak, David P. Ryan, Johanna C. Bendell, Omid Hamid, Wells A. Messersmith, Adil Daud, Razelle Kurzrock, Mariaelena Pierobon, Peng Sun, Elizabeth Cunningham, Shonda M Little, Keith Orford, Monica Motwani, Yuchen Bai, Kiran Klaus Patel, Alan P. Venook, Scott Kopetz - Journal of Clinical Oncology 2015 被引用: 512

  15. A first-in-human study of the anti-LAG-3 antibody favezelimab plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer

    著者: Elena Garralda, Ammar Sukari, Nehal J. Lakhani, Akash Patnaik, Yiyun Lou, Seock‐Ah Im, Talia Golan, Ravit Geva, Martin Wermke, M. de Miguel, J. Palcza, S. Jha, Marya Chaney, Anson K. Abraham, Jasmine Healy, Gerald S. Falchook - ESMO Open 2022 被引用: 88

  16. Sotorasib with panitumumab in chemotherapy-refractory KRASG12C-mutated colorectal cancer: a phase 1b trial

    著者: Yasutoshi Kuboki, Marwan Fakih, John H. Strickler, Rona Yaeger, Toshiki Masuishi, Edward Kim, Christine M. Bestvina, Scott Kopetz, Gerald S. Falchook, Corey J. Langer, John C. Krauss, Sonam Puri, Panli Cardona, Emily Chan, Tracy Varrieur, Lata Mukundan, Abraham Anderson, Qui Tran, David S. Hong - Nature Medicine 2024 被引用: 89

  17. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial

    著者: Gerald S. Falchook, Georgina V. Long, Razelle Kurzrock, Kevin B. Kim, Tobias Arkenau, Michael P. Brown, Omid Hamid, Jeffrey R. Infante, Michael Millward, Anna C. Pavlick, Steven O’Day, Samuel C. Blackman, C. Martin Curtis, Peter F. Lebowitz, Bo Ma, Danièle Ouellet, Richard Kefford - The Lancet 2012 被引用: 933

  18. First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response

    著者: Timothy A. Yap, Justin F. Gainor, Margaret K. Callahan, Gerald S. Falchook, Russell K. Pachynski, Patricia LoRusso, Shivaani Kummar, Geoffrey T. Gibney, Howard A. Burris, Scott S. Tykodi, Osama E. Rahma, Tanguy Y. Seiwert, Kyriakos P. Papadopoulos, Mariela Blum Murphy, Haeseong Park, Amanda Hanson, Yasmin Hashambhoy-Ramsay, Lara McGrath, Ellen Hooper, Xiaoying Xiao, Heather Cohen, Martin Fan, Daniel Felitsky, Courtney Hart, Rachel McComb, Karen Brown, Ali Sepahi, Judith Jiménez, Weidong Zhang, Johan Baeck, Haley Laken, Richard Murray, Elizabeth Trehu, Christopher J. Harvey - Clinical Cancer Research 2022 被引用: 97

  19. Phase 1 trial of TIM-3 inhibitor cobolimab monotherapy and in combination with PD-1 inhibitors nivolumab or dostarlimab (AMBER).

    著者: Gerald S. Falchook, Antoni Ribas, Diwakar Davar, Zeynep Eroglu, Judy S. Wang, Jason J. Luke, Erika Hamilton, Brian Di Pace, Tianli Wang, Srimoyee Ghosh, Arindam Dhar, Theo Borgovan, Angela Waszak, Patricia LoRusso - Journal of Clinical Oncology 2022 被引用: 75

  20. Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid Tumors

    著者: Emerson A. Lim, Johanna C. Bendell, Gerald S. Falchook, Todd M. Bauer, Charles G. Drake, Jennifer H. Choe, Daniel J. George, Janet L. Karlix, Susanna V. Ulahannan, Kris F. Sachsenmeier, Deanna L. Russell, Ganesh Moorthy, Ben S. Sidders, Elizabeth A. Pilling, Huifang Chen, Maureen M. Hattersley, Mayukh Das, Rakesh Kumar, Gayle P. Pouliot, Manish R. Patel - Clinical Cancer Research 2022 被引用: 78

  21. B7-H3 Inhibitors in Oncology Clinical Trials: A Review

    著者: Kavanya Feustel, Jared Martin, Gerald S. Falchook - Journal of Immunotherapy and Precision Oncology 2023 被引用: 73

  22. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial

    著者: Jeffrey R. Infante, Leslie A. Fecher, Gerald S. Falchook, Sujatha Nallapareddy, Michael S. Gordon, Carlos Becerra, Douglas J. DeMarini, Donna S. Cox, Yanmei Xu, Shannon R. Morris, Vijay Peddareddigari, Ngocdiep T. Le, Lowell L. Hart, Johanna C. Bendell, Gail Eckhardt, Razelle Kurzrock, Keith T. Flaherty, Howard A. Burris, Wells A. Messersmith - The Lancet Oncology 2012 被引用: 558

  23. Adenosine Signaling Is Prognostic for Cancer Outcome and Has Predictive Utility for Immunotherapeutic Response

    著者: Ben Sidders, Pei Zhang, Kelly Goodwin, Greg O’Connor, Deanna L. Russell, Alexandra Borodovsky, Joshua Armenia, Robert McEwen, Bolan Linghu, Johanna C. Bendell, Todd M. Bauer, Manish R. Patel, Gerald S. Falchook, Melinda S. Merchant, Gayle P. Pouliot, J. Carl Barrett, Jonathan R. Dry, Rich Woessner, Kris F. Sachsenmeier - Clinical Cancer Research 2020 被引用: 101

  24. A phase 1a/1b trial of CSF-1R inhibitor LY3022855 in combination with durvalumab or tremelimumab in patients with advanced solid tumors

    著者: Gerald S. Falchook, Marc Peeters, Sylvie Rottey, Luc Dirix, Radka Obermannová, Jonathan Cohen, Ruth Perets, Ronnie Shapira Frommer, Todd M. Bauer, Judy S. Wang, Richard D. Carvajal, Joshua K. Sabari, Sonya C. Chapman, Wei Zhang, Boris Calderón, Daniel A. Peterson - Investigational New Drugs 2021 被引用: 58